Trial reportWorld journal of gastroenterology2005
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
Trial report in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Pooled it
- Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.World journal of gastroenterology · 2007Trial
- Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.Clinical trials (London, England) · 2007Trial
- Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes.Molecular immunology · 2020Article
- Psychological Reactions among Patients with Chronic Hepatitis B: a Qualitative Study.Journal of caring sciences · 2016Article
- Inflammatory cytokine-associated depression.Brain research · 2015Review
- Side effects of cytokines approved for therapy.Drug safety · 2014Review
- Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.Journal of psychosomatic research · 2013Article
- The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D).Molecular psychiatry · 2013Article
- Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Neuropsychiatric disease and treatment · 2011Article
- Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.Clinical neuropharmacology · 2010Article
- Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.Psychiatry research · 2010Article
- Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.International journal of methods in psychiatric research · 2007Review
- Psychiatric management of the hepatitis C patient.Current treatment options in gastroenterology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess systematically the spectrum and extent of depressive symptoms comparing patient groups receiving peginterferon or conventional interferon.
methodsNinety-eight patients with chronic hepatitis C and interferon-based therapy (+ribavirin) were consecutively enrolled in a longitudinal study. Patients were treated with conventional interferon alfa-2b (48/98 patients; 5 MIU interferon alfa-2b thrice weekly) or peginterferon alfa-2b (50/98 patients; 80-150 mug peginterferon alfa-2b) in combination with weight-adapted ribavirin (800-1 200 mg/d). Repeated psychometric testing was performed before, three times during and once after antiviral therapy: Depression was evaluated by the Hospital Anxiety and Depression Scale (HADS), anger/hostility by the Symptom Checklist-90 Items Revised (SCL-90-R).
resultsTherapy with pegylated interferon alfa-2b produces comparable scores for depression (ANOVA: P = 0.875) as compared to conventional interferon. Maximums of depression scores were even higher and cases of clinically relevant depression were frequent during therapy with peginterferon. Scores for anger/hostility were comparable for both therapy subgroups.
conclusionOur findings suggest that the extent and frequency of depressive symptoms in total are not reduced by peginterferon. Monitoring and management of neuropsychiatric toxicity especially depression have to be considered as much as in antiviral therapy with unmodified interferon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.